{"id":1084,"date":"2017-12-06T14:40:53","date_gmt":"2017-12-06T13:40:53","guid":{"rendered":"https:\/\/emagazin.plus\/?p=1084"},"modified":"2020-03-26T14:50:06","modified_gmt":"2020-03-26T13:50:06","slug":"liliana-berezkinova-nanopharma","status":"publish","type":"post","link":"https:\/\/emagazin.plus\/cz\/liliana-berezkinova-nanopharma\/","title":{"rendered":"\u0158\u00edkali n\u00e1m amazonky"},"content":{"rendered":"

Lilian\u011b Berezkinov\u00e9 je\u0161t\u011b nebylo t\u0159icet, a p\u0159itom nen\u00ed pouze p\u0159edsedkyn\u00ed p\u0159edstavenstva ve sv\u00e9 firm\u011b Nanopharma, ale tak\u00e9 sed\u00ed v\u00a0dozor\u010d\u00ed rad\u011b biotechnologick\u00e9 skupiny SinBio a klastru Czechimplant a doned\u00e1vna byla \u010dlenkou p\u0159edstavenstva Asociace mal\u00fdch a st\u0159edn\u00edch podnik\u016f. A p\u0159esto u n\u00ed nem\u016f\u017eeme diagnostikovat dramatick\u00e9 sb\u00edr\u00e1n\u00ed funkc\u00ed. Je to v\u00e1\u0161e\u0148. Jej\u00ed pr\u00e1ce se to\u010d\u00ed kolem nanomateri\u00e1l\u016f a zdravotnictv\u00ed. Lili Berezkinov\u00e1 s\u00a0n\u00e1mi hovo\u0159ila tak\u00e9 o tom, jak se mal\u00e1 \u010desk\u00e1 nanofirma prosadila na mezin\u00e1rodn\u00edm poli. A pro\u010d m\u00e1 po narozen\u00ed sv\u00e9 nyn\u00ed dvouap\u016fllet\u00e9 dcery najednou v\u00edce \u010dasu. <\/em><\/p>\n

 <\/p>\n

Pr\u00e1v\u011b jste se vr\u00e1tila z dovolen\u00e9 ve \u0160pan\u011blsku. P\u0159ed p\u011bti lety jste byla na studijn\u00ed st\u00e1\u017ei na IESE Barcelona. S jak\u00fdmi pocity sledujete konflikt mezi Barcelonou a Madridem?<\/strong><\/p>\n

Politick\u00e1 ot\u00e1zka, tak to jsem ne\u010dekala. V Katal\u00e1nsku m\u00e1m spoustu p\u0159\u00e1tel a \u010d\u00e1st m\u00e9 rodiny \u017eije ve \u0160pan\u011blsku. My to vn\u00edm\u00e1me citliv\u011b pohledem v\u011bt\u0161iny, kter\u00e1 nen\u00ed tolik sly\u0161et. A douf\u00e1me, \u017ee celistvost \u0160pan\u011blska z\u016fstane zachov\u00e1na. Bude to dobr\u00e9 jak pro tu zemi, tak pro Evropu jako takovou. Snaha Katal\u00e1nska o samostatnost jde proti dlouhodob\u00fdm snah\u00e1m o evropskou integraci. Mysl\u00edm, \u017ee i v kontextu brexitu a t\u0159eba i p\u0159edchoz\u00edch snah Baskicka o separaci jsou to kroky vedouc\u00ed k oslaben\u00ed Evropy jako kontinentu, jak v ekonomick\u00e9m, tak i politick\u00e9m smyslu.<\/p>\n

Mluvme te\u010f o nanotechnologi\u00edch:<\/strong> Jste p\u0159edsedkyn\u00ed p\u0159edstavenstva firmy Nanopharma. Nanotechnologie je jak\u00e1si tajn\u00e1 inova\u010dn\u00ed zbra\u0148 \u010cesk\u00e9 republiky. V\u0161ude \u010dteme, \u017ee \u010cesko je nano. Jak funguje v\u00e1\u0161 byznys ve zdravotnick\u00e9m pr\u016fmyslu?<\/strong><\/p>\n

Nanopharma je technologick\u00e1 spole\u010dnost, kter\u00e1 postavila sv\u016fj obchodn\u00ed model na dvou sm\u011brech. Jednak fungujeme jako smluvn\u00ed v\u00fdvojov\u00fd partner a pom\u00e1h\u00e1me zdravotnick\u00fdm firm\u00e1m inovovat jejich produkty a s vyu\u017eit\u00edm nanomateri\u00e1l\u016f vyv\u00edjet nov\u00e9. A jednak komercializujeme na\u0161e du\u0161evn\u00ed vlastnictv\u00ed, to znamen\u00e1, \u017ee aktivn\u011b nab\u00edz\u00edme sv\u00e9 technologie a produkty. Nejenom v oblasti zdravotnictv\u00ed, ale t\u0159eba i kosmetiky.<\/p>\n

Kde se dnes daj\u00ed aplikovat \u0159e\u0161en\u00ed Nanopharmy?<\/strong><\/p>\n

To je slo\u017eit\u00e9. Nanotechnologie do zdravotnictv\u00ed pronikaj\u00ed postupn\u011b. V klinick\u00e9m v\u00fdzkumu se u\u017e nyn\u00ed vyu\u017e\u00edvaj\u00ed na\u0161e materi\u00e1ly pro p\u0159\u00edpravu tk\u00e1\u0148ov\u00fdch n\u00e1hrad, kultivaci kmenov\u00fdch bun\u011bk a t\u0159eba i tvorbu um\u011bl\u00fdch org\u00e1n\u016f. To je prvn\u00ed cesta, kde je pot\u0159eba technologii validovat. Kdy\u017e se prok\u00e1\u017ee jej\u00ed funk\u010dnost, postupuje se ke klinick\u00e9mu testov\u00e1n\u00ed a integraci nanotechnologi\u00ed do produkt\u016f a \u0159e\u0161en\u00ed firem, kter\u00e9 vyr\u00e1b\u011bj\u00ed zdravotnick\u00e9 prost\u0159edky nebo hledaj\u00ed nov\u00e9 cesty, jak aplikovat l\u00e9\u010diva.<\/p>\n

U\u017e m\u00e1te n\u011bjak\u00fd patent?<\/strong><\/p>\n

Patent\u016f m\u00e1me \u0159adu. N\u00e1\u0161 hlavn\u00ed patent se t\u00fdk\u00e1 pod\u00e1v\u00e1n\u00ed l\u00e9\u010div prost\u0159ednictv\u00edm nanon\u00e1plasti. To je na\u0161e vlajkov\u00e1 technologie, kter\u00e1 umo\u017e\u0148uje dod\u00e1vat do k\u016f\u017ee l\u00e9\u010diva l\u00e9pe, efektivn\u011bji a ekonomi\u010dt\u011bji ne\u017e nap\u0159\u00edklad sou\u010dasn\u00e9 n\u00e1plasti. Z\u00e1sadn\u00ed rozd\u00edl je v tom, \u017ee na\u0161e n\u00e1plast obsahuje a\u017e o polovinu m\u00e9n\u011b l\u00e9\u010diva, p\u0159i\u010dem\u017e ho do k\u016f\u017ee dod\u00e1 stejn\u011b nebo i v\u00edce, ne\u017e je dnes b\u011b\u017en\u00e9. N\u00e1plast se nav\u00edc na k\u016f\u017ei rozpadne. B\u011b\u017en\u00e1 n\u00e1plast po pou\u017eit\u00ed obsahuje st\u00e1le 90\u00a0% l\u00e9\u010diva a takto se vyhod\u00ed \u2013 s\u00a0vysok\u00fdm rizikem kontaminace i zneu\u017eit\u00ed, nap\u0159\u00edklad u opi\u00e1t\u016f. Na\u0161e technologie tyto nedostatky eliminuje.<\/p>\n

Kde byly nebo jsou nejv\u011bt\u0161\u00ed p\u0159ek\u00e1\u017eky p\u0159i budov\u00e1n\u00ed firmy v bran\u017ei nanotechnologi\u00ed?<\/strong><\/p>\n

P\u0159ekon\u00e1vat skepsi z n\u011b\u010deho nov\u00e9ho, nezn\u00e1m\u00e9ho. P\u0159ed n\u011bkolika lety nanotechnologie nebyly dostate\u010dn\u011b zn\u00e1m\u00e9 a panovalo kolem nich mnoho m\u00fdt\u016f, t\u0159eba ohledn\u011b bezpe\u010dnosti. V\u00fdroba v\u00a0pr\u016fmyslov\u00fdch objemech se etablovala jen velmi postupn\u011b a v\u00a0podstat\u011b skokov\u011b, proto byly nanomateri\u00e1ly jako vstupy zpo\u010d\u00e1tku pom\u011brn\u011b drah\u00e9. Tak\u00e9 chyb\u011bla data k jejich \u00fa\u010dinnosti a bezpe\u010dnosti. Dnes je situace \u00fapln\u011b opa\u010dn\u00e1. Firmy samy aktivn\u011b vyhled\u00e1vaj\u00ed \u0159e\u0161en\u00ed pomoc\u00ed nanotechnologi\u00ed, proto\u017ee vid\u00ed, \u017ee rozm\u011br nano um\u00ed d\u00e1t jejich produkt\u016fm a \u0159e\u0161en\u00edm \u00fapln\u011b novou dimenzi a p\u0159idanou hodnotu.<\/p>\n

\"\"<\/p>\n

Pr\u00e1v\u011b za\u010d\u00e1te\u010dn\u00ed f\u00e1ze je pro nanotechnologick\u00e9 firmy finan\u010dn\u011b n\u00e1ro\u010dn\u00e1. Jakou roli hraj\u00ed investo\u0159i a crowdfunding?<\/strong><\/p>\n

Crowdfunding je u technologick\u00fdch firem velmi atypick\u00e1 z\u00e1le\u017eitost a my k n\u011bmu p\u0159istupujeme a\u017e nyn\u00ed, kdy jsou na\u0161e produkty pro spot\u0159ebitele hmatateln\u00e9. Formou crowdfundingu je mohou vyzkou\u0161et jako prvn\u00ed. Mohou n\u00e1m d\u00e1t zp\u011btnou vazbu a podpo\u0159it n\u00e1s v tom, abychom p\u0159ekonali tu posledn\u00ed bari\u00e9ru, co\u017e je finan\u010dn\u011b n\u00e1kladn\u00fd vstup na trh. V prvn\u00edch f\u00e1z\u00edch vzniku technologick\u00fdch firem jsou ale samoz\u0159ejm\u011b kl\u00ed\u010dov\u00ed investo\u0159i, a\u0165 u\u017e to jsou angel investors, venture kapit\u00e1lov\u00e9 fondy nebo jin\u00e9 entity, kte\u0159\u00ed mus\u00ed vlo\u017eit pom\u011brn\u011b dost kapit\u00e1lu na to, aby z technologi\u00ed vzniklo atraktivn\u00ed portfolio produkt\u016f a aby vzniklo du\u0161evn\u00ed vlastnictv\u00ed. Jenom tvorba a udr\u017eov\u00e1n\u00ed patent\u016f je ot\u00e1zkou milion\u016f.<\/p>\n

Laik m\u00e1 p\u0159edstavu, \u017ee tyto experiment\u00e1ln\u00ed \u010dinnosti pot\u0159ebuj\u00ed z\u00e1zem\u00ed. I laboratorn\u00ed z\u00e1zem\u00ed, kter\u00e9 je drah\u00e9 a kter\u00e9 mohou vytvo\u0159it v podstat\u011b jen velk\u00e9 glob\u00e1ln\u00ed firmy. <\/strong><\/p>\n

Ano, ani my jsme nem\u011bli z\u00e1zem\u00ed laborato\u0159\u00ed a velk\u00e9 v\u00fdroby a do dne\u0161ka ho nem\u00e1me. Postupovali jsme velmi agiln\u00edm modelem. Necht\u011bli jsme m\u00edt hned od za\u010d\u00e1tku p\u0159\u00edli\u0161 vysok\u00e9 fixn\u00ed n\u00e1klady, proto\u017ee jsme nem\u011bli st\u00e1l\u00e9 p\u0159\u00edjmy. A tak jsme sp\u00ed\u0161e vyu\u017e\u00edvali strategick\u00fdch partnerstv\u00ed, pron\u00e1jmu a flexibiln\u011bj\u0161\u00edch zp\u016fsob\u016f p\u0159\u00edstupu k\u00a0infrastruktu\u0159e. I proto jsme v roce 2010 spoluzalo\u017eili nanotechnologick\u00fd klastr Nanoprogress, kter\u00fd budoval svoji infrastrukturu, a my jsme ji jako \u010dlenov\u00e9 flexibiln\u011b vyu\u017e\u00edvali. Dnes je to nejv\u011bt\u0161\u00ed nanotechnologick\u00fd klastr v\u00a0Evrop\u011b. Mysl\u00edm, \u017ee tohle n\u00e1m velmi pomohlo.<\/p>\n

\u010cesk\u00e1 republika v posledn\u00edch letech \u010d\u00edm d\u00e1l v\u00edce investuje do v\u011bdy a v\u00fdzkumu. C\u00edlem jsou zhruba 2,5 % HDP. Jak hodnot\u00edte \u010desk\u00fd ekosyst\u00e9m pro inovace a technologick\u00fd transfer?<\/strong><\/p>\n

Transfer z\u00a0akademick\u00e9ho prost\u0159ed\u00ed do pr\u016fmyslu je u n\u00e1s st\u00e1le v\u00a0plenk\u00e1ch. Dob\u0159e funguje v ur\u010dit\u00fdch odv\u011btv\u00edch, kter\u00e1 maj\u00ed dlouhou tradici, t\u0159eba v automobilov\u00e9m pr\u016fmyslu. Co se t\u00fd\u010de nov\u00fdch technologi\u00ed, jsem velk\u00fdm zast\u00e1ncem transferu od mal\u00fdch technologick\u00fdch firem ke st\u0159edn\u00edm podnik\u016fm a z nich k velk\u00fdm firm\u00e1m. To je n\u011bco, co funguje dob\u0159e v nanotechnologi\u00edch, kde se v\u00a0klastrech, jako je Nanoprogress nebo Czechimplant, sdru\u017euj\u00ed technologick\u00e9 firmy jako Nanopharma s du\u0161evn\u00edm vlastnictv\u00edm a v\u00fdrobn\u00ed firmy, kter\u00e9, aby obst\u00e1ly ve sv\u011btov\u00e9 konkurenci, aktivn\u011b vyhled\u00e1vaj\u00ed nov\u00e9 materi\u00e1ly a nov\u00e9 technologie a inovuj\u00ed rychleji a dynami\u010dt\u011bji ne\u017e t\u0159eba velk\u00e1 korporace.<\/p>\n

Je \u010cesko v\u00a0t\u00e9to oblasti konkurenceschopn\u00e9 v\u00a0glob\u00e1ln\u00edm m\u011b\u0159\u00edtku?<\/strong><\/p>\n

V oblasti nanotechnologi\u00ed bezesporu. Ale druh\u00e1 v\u011bc je um\u011bt ty technologie prodat a dostat je na trh. A tam si mysl\u00edm, \u017ee nejen \u010cesk\u00e1 republika, ale cel\u00e1 Evropa jsou oproti t\u0159eba Asii nebo USA stati\u010dt\u011bj\u0161\u00ed.<\/p>\n

\u0158\u00edk\u00e1 se, \u017ee \u010ce\u0161i neum\u00ed prod\u00e1vat. \u010c\u00edm to je?<\/strong><\/p>\n

T\u011b\u017eko \u0159\u00edct. Asi jsme zvykl\u00ed b\u00fdt t\u00edm prost\u0159edn\u00edkem, t\u00edm mezi\u010dl\u00e1nkem. Obecn\u011b je velmi t\u011b\u017ek\u00e9 prod\u00e1vat technologie. Zakladatel\u00e9 technologick\u00fdch firem typicky maj\u00ed bl\u00ed\u017ee k\u00a0technick\u00e9mu zdokonalov\u00e1n\u00ed produktu ne\u017e k jeho prodeji. Je d\u016fle\u017eit\u00e9 dob\u0159e sestavit t\u00fdm, vybalancovat in\u017een\u00fdrstv\u00ed a odbornou znalost i obchodn\u00edm talentem a drivem.<\/p>\n

 <\/p>\n

V N\u011bmecku existuje Fraunhofer-Gesellschaft. V \u010cesku takov\u00e9 efektivn\u00ed poj\u00edtko mezi v\u011bdou a v\u00fdzkumem a byznysem nem\u00e1me. Nepot\u0159ebuje \u010cesk\u00e1 republika n\u011bco podobn\u00e9ho?<\/strong><\/p>\n

 <\/p>\n

Ur\u010dit\u011b, ale nev\u00edm, jestli u\u017e nen\u00ed pozd\u011b. V\u00fdzkumn\u00fdch instituc\u00ed a apar\u00e1t\u016f tady m\u00e1me v\u00edce ne\u017e dost. Probl\u00e9m je, \u017ee nejsou integrovan\u00e9. Ur\u010dit\u011b bychom se ale mohli inspirovat t\u00edm, \u017ee nap\u0159\u00edklad Fraunhoferovy instituty nesou zodpov\u011bdnost za to, aby jejich v\u00fdzkum vedl k v\u00fdsledk\u016fm a byl komer\u010dn\u011b atraktivn\u00ed. Fraunhoferovy instituty z\u00edsk\u00e1vaj\u00ed jenom 30 % zdroj\u016f od st\u00e1tu a zbytek mus\u00ed z\u00edskat samy prost\u0159ednictv\u00edm partnerstv\u00ed nebo z \u010dist\u011b komer\u010dn\u00edch produkt\u016f \u010di slu\u017eeb.<\/p>\n

 <\/p>\n

Vy jste m\u011bli p\u0159ed p\u011bti lety \u0161t\u011bst\u00ed, \u017ee v\u00e1s oslovili brit\u0161t\u00ed a ameri\u010dt\u00ed v\u011bdci. M\u00e1te n\u011bjak\u00fd tip pro mladou \u010deskou firmu, jak vybudovat zahrani\u010dn\u00ed spolupr\u00e1ci?<\/strong><\/p>\n

 <\/p>\n

V\u00a0prv\u00e9 \u0159ad\u011b mus\u00edte svou firmu dob\u0159e zn\u00e1t a v\u011bd\u011bt, v \u010dem je unik\u00e1tn\u00ed a co m\u016f\u017ee nab\u00eddnout. Tuto pozici mus\u00edte napojit na pot\u0159eby trhu. A potom p\u0159ich\u00e1z\u00ed ta mraven\u010d\u00ed pr\u00e1ce, kdy se mus\u00edte vydat do zahrani\u010d\u00ed a hovo\u0159it s firmami, s r\u016fzn\u00fdmi typy firem, a b\u00fdt odm\u00edt\u00e1ni a postupn\u011b zdokonalovat schopnost sebeprezentace. Mal\u00e1 firma nem\u016f\u017ee b\u00fdt l\u00edn\u00e1, mus\u00ed si vytvo\u0159it velkou kritickou masu p\u0159\u00edle\u017eitost\u00ed, ze kter\u00fdch vznikaj\u00ed cenn\u00e1 strategick\u00e1 partnerstv\u00ed. Tohle se n\u00e1m vyplatilo s na\u0161\u00edm australsk\u00fdm partnerem, se kter\u00fdm jsme vyvinuli ji\u017e zmi\u0148ovanou n\u00e1plast. \u010casto \u0159\u00edk\u00e1me jako bonmot, \u017ee s firmou, kter\u00e1 je v\u00a0Austr\u00e1lii, komunikujeme l\u00e9pe a rychleji ne\u017e s n\u011bkter\u00fdmi firmami, kter\u00e9 m\u00e1me za rohem. To v\u0161echno je v\u00fdsledkem toho, \u017ee jsme od za\u010d\u00e1tku v\u011bnovali hodn\u011b \u010dasu a zdroj\u016f tomu, abychom byli mezin\u00e1rodn\u011b p\u0159\u00edtomni.<\/p>\n

 <\/p>\n

Brali v\u00e1s jako malou \u010deskou firmu v\u00e1\u017en\u011b? <\/strong><\/p>\n

 <\/p>\n

P\u0159ed p\u011bti lety to bylo trochu slo\u017eit\u011bj\u0161\u00ed a museli jsme vyu\u017e\u00edvat i pomoci r\u016fzn\u00fdch influencer\u016f a key opinion leader\u016f v oboru, kte\u0159\u00ed n\u00e1m tro\u0161ku otv\u00edrali dve\u0159e. Bylo to t\u011b\u017ek\u00e9. Nejen proto, \u017ee jsme byli \u010desk\u00e1 firma, ale nav\u00edc jsme byli firma pln\u00e1 mlad\u00fdch lid\u00ed. Tak\u017ee atypick\u00e9. Ale mo\u017en\u00e1 nakonec ta atypi\u010dnost zaujala nejv\u00edc.<\/p>\n

\"\"<\/p>\n

Mluv\u00edte p\u011bti jazyky, vedle \u010de\u0161tiny je\u0161t\u011b plynule n\u011bmecky, anglicky, \u0161pan\u011blsky a trochu rusky. V\u00e1\u0161 otec je z Ukrajiny, z Krymu. Co znamenaj\u00ed zku\u0161enosti ze zahrani\u010d\u00ed a znalost ciz\u00edch jazyk\u016f pro v\u00e1s osobn\u011b a pro dne\u0161n\u00ed sv\u011bt byznysu?<\/strong><\/p>\n

 <\/p>\n

Je to naprosto nezbytn\u00fd faktor pro to d\u011blat cokoliv. Mn\u011b vyr\u016fst\u00e1n\u00ed v mezin\u00e1rodn\u00edm prost\u0159ed\u00ed pomohlo m\u00edt otev\u0159enou mysl, ale z\u00e1rove\u0148 tak\u00e9 vid\u011bt zahrani\u010d\u00ed st\u0159\u00edzliv\u011b, neidealizovat si ho. Znalosti ciz\u00edch jazyk\u016f tak\u00e9 otv\u00edraj\u00ed nov\u00e9 p\u0159\u00edle\u017eitosti p\u0159\u00edstupu k informac\u00edm, navazov\u00e1n\u00ed kontakt\u016f a mysl\u00edm si, \u017ee podn\u011bcuj\u00ed zv\u00eddavost, sni\u017euj\u00ed b\u00e1zlivost p\u0159i kontaktu s lidmi a s nov\u00fdmi p\u0159\u00edle\u017eitostmi. Kdy\u017e jsem vyr\u016fstala j\u00e1, byla to v\u00fdhoda. Dnes je to nezbytnost.<\/p>\n

 <\/p>\n

Va\u0161e kari\u00e9ra byla takov\u00e1 rychlokari\u00e9ra. Nejd\u0159\u00edv CEO, pak \u010dlenka p\u0159edstavenstva, p\u0159edsedkyn\u011b p\u0159edstavenstva v Nanopharm\u011b. Jak k\u00a0tomu do\u0161lo? Zn\u00ed to trochu jako z poh\u00e1dky.<\/strong><\/p>\n

 <\/p>\n

Vedouc\u00ed m\u00e9 bakal\u00e1\u0159sk\u00e9 pr\u00e1ce na univerzit\u011b byl zakladatelem Nanopharmy a rozhodl se podstoupit riziko a sv\u011b\u0159it mladou atypickou firmu mlad\u00e9mu \u010dlov\u011bku, kter\u00fd sice nem\u011bl zku\u0161enosti, ale nem\u011bl ani \u0161patn\u00e9 n\u00e1vyky. Oba jsme \u0161li do rizika. A proto\u017ee m\u00e1m r\u00e1da v\u00fdzvy, vzdala jsem se sv\u00fdch pl\u00e1n\u016f na studium a \u017eivot v N\u011bmecku a chytla se zaj\u00edmav\u00e9 pracovn\u00ed p\u0159\u00edle\u017eitosti. U\u017e spolu fungujeme pom\u011brn\u011b dlouho a mysl\u00edm, \u017ee \u00fasp\u011b\u0161n\u011b.<\/p>\n

 <\/p>\n

Studovala jste obor \u0159\u00edzen\u00ed podniku a podnikov\u00e9 finance. Co jste si vzala ze studia a co v\u00e1s mohla nau\u010dit jenom tvrd\u00e1 realita ve firm\u011b?<\/strong><\/p>\n

 <\/p>\n

Ze \u0161koly jsem si odnesla takov\u00e9 ty tvrd\u00e9 znalosti. Jak pracovat s finan\u010dn\u00edmi v\u00fdkazy, \u0159\u00eddit cashflow, v\u0161echno to, co se t\u00fdk\u00e1 \u010d\u00edsel. To, co jsem si neodnesla a musela se nau\u010dit vlastn\u00ed iniciativou a zku\u0161enostmi, byly ty jemn\u00e9 dovednosti. Jak \u0159\u00eddit t\u00fdm, jak ho vybudovat, jak vytvo\u0159it obchodn\u00ed model pro n\u011bco, co nem\u00e1 precedens na trhu. To v\u0161echno jsem musela vyzkou\u0161et sama. \u0158\u00edkala jsem si, \u017ee mus\u00edm pracovat s intuic\u00ed a po\u010d\u00edtat s t\u00edm, \u017ee cestou ud\u011bl\u00e1m p\u00e1r chyb.<\/p>\n

 <\/p>\n

M\u00e1te to jako \u017eena ve vysok\u00e9m managementu t\u011b\u017e\u0161\u00ed?<\/strong><\/p>\n

 <\/p>\n

To si nep\u0159ipou\u0161t\u00edm. Z\u00e1le\u017e\u00ed na tom, s k\u00fdm jedn\u00e1te. Pokud jedn\u00e1te s profesion\u00e1ln\u00edm a dob\u0159e vychovan\u00fdm \u010dlov\u011bkem, tak to, \u017ee jsem \u017eena, nehraje \u017e\u00e1dnou roli. Pokud takov\u00e9 \u0161t\u011bst\u00ed nem\u00e1m, sna\u017e\u00edm se na to nemyslet.<\/p>\n

 <\/p>\n

Tak\u017ee to ne\u0159e\u0161\u00edte?<\/strong><\/p>\n

 <\/p>\n

Ne. Nav\u00edc jsme firma, kter\u00e1 m\u00e1 kompletn\u011b \u017eensk\u00e9 p\u0159edstavenstvo. Firmu jsme rozj\u00ed\u017ed\u011bly jako \u017eeny, \u0159\u00edkali n\u00e1m amazonky. Nebyl to z\u00e1m\u011br, tak to vzniklo, tak\u017ee jsme se touto ot\u00e1zkou nikdy moc nezab\u00fdvaly.<\/p>\n

 <\/p>\n

M\u00e1te malou dceru, te\u010f j\u00ed je dva a p\u016fl roku. Zm\u011bnil tento fakt n\u011bco ohledn\u011b va\u0161\u00ed pr\u00e1ce?<\/strong><\/p>\n

 <\/p>\n

P\u0159edn\u011b jsem velmi r\u00e1da, \u017ee si mohu u\u017e\u00edvat jak mate\u0159stv\u00ed, tak sv\u00e9 pr\u00e1ce. Asi jako v\u0161ichni mus\u00edm l\u00e9pe pl\u00e1novat. A paradoxn\u011b jsem zjistila, \u017ee te\u010f m\u00e1m v\u00edce \u010dasu, ne\u017e jsem si myslela. \u010clov\u011bk po tom, co se mu narod\u00ed d\u00edt\u011b, u\u017e nen\u00ed stejn\u00fd. V\u0161echno se n\u011bjak\u00fdm zp\u016fsobem zm\u011bn\u00ed, ale v pozitivn\u00edm smyslu, hovo\u0159\u00edm hlavn\u011b o hodnot\u00e1ch a \u017eivotn\u00edch priorit\u00e1ch. Za sebe m\u016f\u017eu \u0159\u00edct, \u017ee mi d\u00edt\u011b d\u00e1v\u00e1 neutuchaj\u00edc\u00ed zdroj radosti, v\u011bt\u0161\u00ed pohodu a v\u011bt\u0161\u00ed klid, co\u017e se p\u0159\u00edzniv\u011b projevuje i na tom, jak se vypo\u0159\u00e1d\u00e1v\u00e1m s\u00a0v\u00fdzvami v\u00a0byznysu.<\/p>\n

\"\"<\/p>\n

Co o\u010dek\u00e1v\u00e1te od p\u0159\u00ed\u0161t\u00ed vl\u00e1dy \u2013 co by usnadnilo v\u00e1\u0161 byznys?<\/strong><\/p>\n

 <\/p>\n

O\u010dek\u00e1v\u00e1m, \u017ee \u010desk\u00e1 vl\u00e1da jasn\u011b nastav\u00ed dlouhodobou vizi pro konkurenceschopnost \u010desk\u00e9 ekonomiky a \u017ee do t\u00e9 vize zahrne i nov\u00e9 technologie a slu\u017eby s vysokou p\u0159idanou hodnotou.<\/p>\n

 <\/p>\n

Anga\u017eujete se v Asociaci mal\u00fdch a st\u0159edn\u00edch podnik\u016f, ve spolupr\u00e1ci s Karlem Havl\u00ed\u010dkem. Vedete projekt Svou cestou \u2013 Young Business. Je klima v \u010cesk\u00e9 republice pro za\u010d\u00ednaj\u00edc\u00ed podnikatele dobr\u00e9?<\/strong><\/p>\n

 <\/p>\n

Je lep\u0161\u00ed, ne\u017e bylo v roce 2013, kdy jsme tento projekt zakl\u00e1dali. Za\u010d\u00ednaj\u00edc\u00ed podnikatel\u00e9 dnes maj\u00ed lep\u0161\u00ed p\u0159\u00edstup ke kapit\u00e1lu, k seedov\u00e9mu financov\u00e1n\u00ed. Je to i d\u00edky roz\u0161\u00ed\u0159en\u00ed crowdfundingu, ale i d\u00edky tomu, \u017ee se na jejich podporu zam\u011b\u0159uj\u00ed jak st\u00e1tn\u00ed instituce, tak priv\u00e1tn\u00ed subjekty. V tomto ohledu je to lep\u0161\u00ed. Nejv\u00edc si mlad\u00ed za\u010d\u00ednaj\u00edc\u00ed podnikatel\u00e9 st\u011b\u017euj\u00ed na byrokracii a na to, \u017ee mo\u017enost zalo\u017eit firmu nen\u00ed digitalizovan\u00e1. Ale popravd\u011b \u0159e\u010deno, jsou to p\u0159ek\u00e1\u017eky, kter\u00e9 n\u011bkoho, kdo chce za\u010d\u00edt podnikat, neodrad\u00ed. Tak\u017ee celkov\u011b bych to vid\u011bla sp\u00ed\u0161 pozitivn\u011b. Mysl\u00edm, \u017ee klima se postupn\u011b lep\u0161\u00ed.<\/p>\n

 <\/p>\n

Na webu tohoto projektu se p\u00ed\u0161e \u201eNebu\u010f p\u011b\u0161\u00e1kem u jin\u00fdch, rozhoduj s\u00e1m!\u201c Vy sama jste nikdy nebyla dlouho p\u011b\u0161\u00e1kem.<\/strong><\/p>\n

 <\/p>\n

Ano, asi ani nikdy nebudu.<\/p>\n

 <\/p>\n

Pan\u00ed Berezkinov\u00e1, d\u011bkuji v\u00e1m za rozhovor.<\/strong><\/p>\n

 <\/p>\n

Autor: Christian R\u00fchmkorf<\/p>\n

Zdroj \u00favodn\u00ed fotky:\u00a0Tom\u00e1\u0161 \u017delezn\u00fd<\/p>\n","protected":false},"excerpt":{"rendered":"

Lilian\u011b Berezkinov\u00e9 je\u0161t\u011b nebylo t\u0159icet, a p\u0159itom nen\u00ed pouze p\u0159edsedkyn\u00ed p\u0159edstavenstva ve sv\u00e9 firm\u011b Nanopharma, ale tak\u00e9 sed\u00ed v dozor\u010d\u00ed rad\u011b biotechnologick\u00e9 skupiny SinBio a klastru Czechimplant a doned\u00e1vna byla \u010dlenkou p\u0159edstavenstva Asociace mal\u00fdch a st\u0159edn\u00edch podnik\u016f. A p\u0159esto u n\u00ed nem\u016f\u017eeme diagnostikovat dramatick\u00e9 sb\u00edr\u00e1n\u00ed funkc\u00ed. Je to v\u00e1\u0161e\u0148. Jej\u00ed pr\u00e1ce se to\u010d\u00ed kolem nanomateri\u00e1l\u016f a zdravotnictv\u00ed. Lili Berezkinov\u00e1 s n\u00e1mi hovo\u0159ila tak\u00e9 o tom, jak se mal\u00e1 \u010desk\u00e1 nanofirma prosadila na mezin\u00e1rodn\u00edm poli. A pro\u010d m\u00e1 po narozen\u00ed sv\u00e9 nyn\u00ed dvouap\u016fllet\u00e9 dcery najednou v\u00edce \u010dasu. <\/p>\n","protected":false},"author":1,"featured_media":1085,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[8,60],"tags":[3,61,73,78,235],"class_list":["post-1084","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-interviewrozhovor","category-plus-052017","tag-startup","tag-gesundheitsbranche","tag-medizintechnik","tag-nanotechnologie","tag-finanzierung"],"translation":{"provider":"WPGlobus","version":"3.0.0","language":"cz","enabled_languages":["de","cz"],"languages":{"de":{"title":true,"content":true,"excerpt":true},"cz":{"title":true,"content":true,"excerpt":true}}},"yoast_head":"\nNanopharma Vorstandsvorsitzende Liliana Berezkinov\u00e1 - Magazin Plus<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u0158\u00edkali n\u00e1m amazonky - Plus\" \/>\n<meta property=\"og:url\" content=\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Plus\" \/>\n<meta property=\"article:published_time\" content=\"2017-12-06T13:40:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-03-26T13:50:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/emagazin.plus\/wp-content\/uploads\/2017\/12\/IMG_3862-e1568275812518.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Plus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Plus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"26 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/\"},\"author\":{\"name\":\"Plus\",\"@id\":\"https:\/\/emagazin.plus\/#\/schema\/person\/37cd14efd2ba64045e168f219e9bd960\"},\"headline\":\"\u0158\u00edkali n\u00e1m amazonky\",\"datePublished\":\"2017-12-06T13:40:53+00:00\",\"dateModified\":\"2020-03-26T13:50:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/\"},\"wordCount\":5152,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/emagazin.plus\/#organization\"},\"image\":{\"@id\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/emagazin.plus\/wp-content\/uploads\/2017\/12\/IMG_3862-e1568275812518.jpg\",\"keywords\":[\"Startup\",\"Gesundheitsbranche\",\"Medizintechnik\",\"Nanotechnologie\",\"Finanzierung\"],\"articleSection\":[\"Rozhovor\",\"Zdravotnick\u00fd pr\u016fmysl - 05\/2017\"],\"inLanguage\":\"cz\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/\",\"url\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/\",\"name\":\"Nanopharma Vorstandsvorsitzende Liliana Berezkinov\u00e1 - Magazin Plus\",\"isPartOf\":{\"@id\":\"https:\/\/emagazin.plus\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/emagazin.plus\/wp-content\/uploads\/2017\/12\/IMG_3862-e1568275812518.jpg\",\"datePublished\":\"2017-12-06T13:40:53+00:00\",\"dateModified\":\"2020-03-26T13:50:06+00:00\",\"description\":\"Liliana Berezkinov\u00e1 berichtet \u00fcber ihrer Firma Nanopharma und \u00fcber die gr\u00f6\u00dften H\u00fcrden beim Aufbau eines Unternehmens in der Nano-Branche.\",\"breadcrumb\":{\"@id\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#breadcrumb\"},\"inLanguage\":\"cz\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"cz\",\"@id\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#primaryimage\",\"url\":\"https:\/\/emagazin.plus\/wp-content\/uploads\/2017\/12\/IMG_3862-e1568275812518.jpg\",\"contentUrl\":\"https:\/\/emagazin.plus\/wp-content\/uploads\/2017\/12\/IMG_3862-e1568275812518.jpg\",\"width\":1000,\"height\":667,\"caption\":\"Interview Liliana Berezkinov\u00e1 Nanopharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/emagazin.plus\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sie nannten uns Amazonen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/emagazin.plus\/#website\",\"url\":\"https:\/\/emagazin.plus\/\",\"name\":\"Plus\",\"description\":\"magaz\u00edn \u010desko-n\u011bmeck\u00e9ho hospod\u00e1\u0159tv\u00ed\",\"publisher\":{\"@id\":\"https:\/\/emagazin.plus\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/emagazin.plus\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"cz\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/emagazin.plus\/#organization\",\"name\":\"Plus\",\"url\":\"https:\/\/emagazin.plus\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"cz\",\"@id\":\"https:\/\/emagazin.plus\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/emagazin.plus\/wp-content\/uploads\/2020\/01\/cropped-Logo-3.png\",\"contentUrl\":\"https:\/\/emagazin.plus\/wp-content\/uploads\/2020\/01\/cropped-Logo-3.png\",\"width\":1017,\"height\":221,\"caption\":\"Plus\"},\"image\":{\"@id\":\"https:\/\/emagazin.plus\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/emagazin.plus\/#\/schema\/person\/37cd14efd2ba64045e168f219e9bd960\",\"name\":\"Plus\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"cz\",\"@id\":\"https:\/\/emagazin.plus\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/df44f54cca64602185ca76698560e71e98255ae7be0e43f561f7df4e36cea218?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/df44f54cca64602185ca76698560e71e98255ae7be0e43f561f7df4e36cea218?s=96&d=mm&r=g\",\"caption\":\"Plus\"},\"url\":\"https:\/\/emagazin.plus\/cz\/author\/plus\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanopharma Vorstandsvorsitzende Liliana Berezkinov\u00e1 - Magazin Plus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/","og_locale":"en_US","og_type":"article","og_title":"\u0158\u00edkali n\u00e1m amazonky - Plus","og_url":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/","og_site_name":"Plus","article_published_time":"2017-12-06T13:40:53+00:00","article_modified_time":"2020-03-26T13:50:06+00:00","og_image":[{"width":1000,"height":667,"url":"https:\/\/emagazin.plus\/wp-content\/uploads\/2017\/12\/IMG_3862-e1568275812518.jpg","type":"image\/jpeg"}],"author":"Plus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Plus","Est. reading time":"26 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#article","isPartOf":{"@id":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/"},"author":{"name":"Plus","@id":"https:\/\/emagazin.plus\/#\/schema\/person\/37cd14efd2ba64045e168f219e9bd960"},"headline":"\u0158\u00edkali n\u00e1m amazonky","datePublished":"2017-12-06T13:40:53+00:00","dateModified":"2020-03-26T13:50:06+00:00","mainEntityOfPage":{"@id":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/"},"wordCount":5152,"commentCount":0,"publisher":{"@id":"https:\/\/emagazin.plus\/#organization"},"image":{"@id":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#primaryimage"},"thumbnailUrl":"https:\/\/emagazin.plus\/wp-content\/uploads\/2017\/12\/IMG_3862-e1568275812518.jpg","keywords":["Startup","Gesundheitsbranche","Medizintechnik","Nanotechnologie","Finanzierung"],"articleSection":["Rozhovor","Zdravotnick\u00fd pr\u016fmysl - 05\/2017"],"inLanguage":"cz","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/","url":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/","name":"Nanopharma Vorstandsvorsitzende Liliana Berezkinov\u00e1 - Magazin Plus","isPartOf":{"@id":"https:\/\/emagazin.plus\/#website"},"primaryImageOfPage":{"@id":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#primaryimage"},"image":{"@id":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#primaryimage"},"thumbnailUrl":"https:\/\/emagazin.plus\/wp-content\/uploads\/2017\/12\/IMG_3862-e1568275812518.jpg","datePublished":"2017-12-06T13:40:53+00:00","dateModified":"2020-03-26T13:50:06+00:00","description":"Liliana Berezkinov\u00e1 berichtet \u00fcber ihrer Firma Nanopharma und \u00fcber die gr\u00f6\u00dften H\u00fcrden beim Aufbau eines Unternehmens in der Nano-Branche.","breadcrumb":{"@id":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#breadcrumb"},"inLanguage":"cz","potentialAction":[{"@type":"ReadAction","target":["https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/"]}]},{"@type":"ImageObject","inLanguage":"cz","@id":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#primaryimage","url":"https:\/\/emagazin.plus\/wp-content\/uploads\/2017\/12\/IMG_3862-e1568275812518.jpg","contentUrl":"https:\/\/emagazin.plus\/wp-content\/uploads\/2017\/12\/IMG_3862-e1568275812518.jpg","width":1000,"height":667,"caption":"Interview Liliana Berezkinov\u00e1 Nanopharma"},{"@type":"BreadcrumbList","@id":"https:\/\/emagazin.plus\/liliana-berezkinova-nanopharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/emagazin.plus\/"},{"@type":"ListItem","position":2,"name":"Sie nannten uns Amazonen"}]},{"@type":"WebSite","@id":"https:\/\/emagazin.plus\/#website","url":"https:\/\/emagazin.plus\/","name":"Plus","description":"magaz\u00edn \u010desko-n\u011bmeck\u00e9ho hospod\u00e1\u0159tv\u00ed","publisher":{"@id":"https:\/\/emagazin.plus\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/emagazin.plus\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"cz"},{"@type":"Organization","@id":"https:\/\/emagazin.plus\/#organization","name":"Plus","url":"https:\/\/emagazin.plus\/","logo":{"@type":"ImageObject","inLanguage":"cz","@id":"https:\/\/emagazin.plus\/#\/schema\/logo\/image\/","url":"https:\/\/emagazin.plus\/wp-content\/uploads\/2020\/01\/cropped-Logo-3.png","contentUrl":"https:\/\/emagazin.plus\/wp-content\/uploads\/2020\/01\/cropped-Logo-3.png","width":1017,"height":221,"caption":"Plus"},"image":{"@id":"https:\/\/emagazin.plus\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/emagazin.plus\/#\/schema\/person\/37cd14efd2ba64045e168f219e9bd960","name":"Plus","image":{"@type":"ImageObject","inLanguage":"cz","@id":"https:\/\/emagazin.plus\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/df44f54cca64602185ca76698560e71e98255ae7be0e43f561f7df4e36cea218?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/df44f54cca64602185ca76698560e71e98255ae7be0e43f561f7df4e36cea218?s=96&d=mm&r=g","caption":"Plus"},"url":"https:\/\/emagazin.plus\/cz\/author\/plus\/"}]}},"cc_featured_image_caption":{"caption_text":"","source_text":"","source_url":""},"_links":{"self":[{"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/posts\/1084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/comments?post=1084"}],"version-history":[{"count":10,"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/posts\/1084\/revisions"}],"predecessor-version":[{"id":5281,"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/posts\/1084\/revisions\/5281"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/media\/1085"}],"wp:attachment":[{"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/media?parent=1084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/categories?post=1084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/emagazin.plus\/cz\/wp-json\/wp\/v2\/tags?post=1084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}